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Abstract
Background: In Italy, anti-HCV drugs are provided free of charge by the National Health System. Since 2011, three
drug regimens including a directly acting antiviral (DAA) are considered the gold standard for HCV treatment.
However, these drugs add a significant cost (roughly €26,000) to the combination of pegylated-interferon-a/
ribavirin (PEG-IFN/RBV), which before DAA represented the unique treatment. To provide the National Health
System potential useful information, we estimated costs to provide anti-HCV drugs to treat a population
experienced for PEG-INF/RBV.
Methods: Genotype 1 HCV mono-infected or HIV/HCV co-infected individuals who were treated with PEG-IFN/RBV
between 2008 and 2013 were included. The cost to treat these patients with PEG-IFN/RBV was calculated (cost 1).
We also estimated costs if we had to treat these patients with a lead-in period of PEG-INF/RBV followed by PEG-
IFN/RBV and a DAA in naïves (cost 2), in addition to cost 1 plus the estimated cost to re-treat with PEG-IFN/RBV
and a DAA patients who had a relapse or a non response (cost 3). Moreover, all costs were normalized by SVR.
Rates of foreseen response with DAA were obtained from literature data.
Results: The overall study population consisted of 104 patients. The rate of sustained virological response (SVR)
was 55%, while it was estimated that SVR would be obtained in 75% of patients with a lead-in period with PEG-
IFN/RBV followed by a DAA combination, and in 78% if this treatment is used to re-treat experienced patients with
a DAA. Drug costs associated with these treatments were: €1,214,283 for cost 1, €3,474,977 for cost 2 and
€3,002,095 for cost 3. Costs per SVR achieved were: €22,284 for cost 1, €44,643 for cost 2 and €38,322 for cost 3.
Conclusions: Treatments including DAAs achieve a SVR in more patients than PEG-IFN/RBV but they cost around
three times more than PEG-IFN/RBV alone regimens. Also, cost per SVR is almost twofold greater than PEG-IFN/RBV
regimens. Therefore, it is mandatory to implement use of DAA in clinical practice, but the National Health System
should allocate adequate resources to provide drugs, which challenges sustainability. Cost reduction for anti-HCV
drugs should be pursued.
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Background
It is estimated that hepatitis C virus (HCV) infects more
than 170 million people worldwide, with 17 million of
them living in the Mediterranean region. In Italy, preva-
lence is 3-4.4%, with peaks reported in Southern regions
(12.6-26%) [1-4]. The standard of care for treatment has
been represented by a combination of pegylated interferon-
a (PEG-IFN) and ribavirin (RBV) for all HCV genotypes.
However, the treatment response of genotype 1 HCV after
PEG-IFN/RBV is not acceptable when compared to PEG-
IFN/RBV in combination with the new directly acting anti-
virals (DAA), which are now recommended as the standard
of care for treatment of patients infected by this genotype
[5,6]. Currently, in Italy, boceprevir (BOC) and telaprevir
(TPR) are the only available and recommended DAAs [7].
In Italy, current recommended drugs are provided free
of charge to patients in need. DAA’s increase the cost of
therapy to a significant extent (by roughly €26,000). For
this reason, in the current economical crisis and from the
payer perspective of National Health System (NHS), it is
difficult to convince authorities to extend prescription of
these regimens to a large number of patients. In addition,
it is important to provide authorities with estimates of
resources needed to treat patients.
With this objective in mind, we calculated the actual
costs to treat these patients and estimated costs to treat
with a DAA the same population of naïve patients or to
re-treat with a DAA only those who did not respond to
the previous regimen (PEG-IFN/RBV).
Methods
The study was conducted in three Units, two located in
Southern Italy (Hepatology Unit of the University Hospital
“Mater Domini” Catanzaro and Infectious Disease Unit in
the same Hospital), and one located in Northern Italy
(Unit of Infectious Diseases of the University of Padua).
Patients from the University of Padua were co-infected
with human immunodeficiency virus (HIV), while those
from the University Hospital “Mater Domini” in Catanzaro
were HCV mono-infected. The study was conducted under
the provisions of the Declaration of Helsinki, and in accor-
dance with the International Conference on Harmoniza-
tion Consolidated Guideline on Good Clinical Practice. As
this study was retrospective and non-pharmacological,
written informed consent has not been provided. Approval
was obtained from the local ethical committee of the
“Mater Domini” Teaching Hospital.
An observational study was performed, including all
HCV-genotype 1 infected patients, treated with PEG-
IFN/RBV from January 1, 2008 to June 30, 2013. A
cost-consequences analysis was assessed and incremen-
tal costs of therapies were computed and listed.
We compared the actual cost for treatment of naive
patients with PEG-IFN/RBV (cost 1), versus the estimated
cost that would have been spent to treat the same patients
with PEG-IFN/RBV in combination with a DAA (cost 2),
versus cost 1 plus the estimated additional cost for retreat-
ment of patients who did not respond to PEG-IFN/RBV if
a DAA would have been added for re-treatment (cost 3).
For cost 2 estimation, initial treatment for 4 weeks (so
called “lead-in”) with PEG-IFN/RBV was assumed prior
to the addition of a DAA for 12 weeks (if needed depend-
ing on achievement of a rapid virological response, RVR),
then followed by PEG-IFN/RBV for 12 to 36 weeks
depending on HCV RNA levels at weeks 4 and 12 [7,8].
Costs were normalized for sustained virological response
(SVR) derived from results of the ADVANCE trial [9].
According to this trial, a 75% rate of SVR in patients
naïve to PEG-IFN/RBV was used for estimating cost 2.
For cost 3, the estimated cost for retreating with PEG-
IFN/RBV and a DAA (in case of a non response or
relapse) was added to cost 1. We hypothesized that
12 weeks of a 3-drug regimen is prescribed, followed by
36 weeks of PEG-IFN/RBV combination in all patients
[7]. Proportions of SVR for cost normalization (cost per
SVR achieved) were derived from the REALIZE trial
[10]. They were 29% for null responders, 59% for partial
responders and 83% for patients who had a virological
relapse.
Drug costs per week were based on an article by
Cammà et al. [11]: €165.57 for PEG-IFN, €106.15 for
RBV and €2,083.00 for TPR (assumed as reference DAA).
Discounted rate was not applied for cost estimations.
Results
A total of 104 patients were included in the study.
Patient characteristics and response to treatment (either
actually achieved or estimated for cost calculation) are
shown in Table 1. HIV/HCV co-infected patients were
26%, females were 59%, the most frequent infecting gen-
otype was 1b, and median age was 47 years (interquar-
tile range - IQR 17).
Treatment with PEG-IFN/RBV was completed by 89 of
104 patients (85%). In other patients, interruption of treat-
ment was due to decision of patient (2%), drug related side
effects (9%) and viral failure (4%). Rate of SVR was 55%
overall (22% males, 33% females), while it was 60% among
HCV mono-infected patients and 41% among HIV/HCV
co-infected ones. Virological relapse was observed in 15%
patients in both HCV mono-infected and HIV/HCV
co-infected groups. Patients had a partial response in 6%
of cases (15% among HIV/HCV co-infected and 3%
among HCV mono-infected patients). Null responders
were 24% (29% HIV/HCV co-infected and 22% HCV
mono-infected patients). A RVR was reached in 9%
patients, 48% reached SVR without RVR and 43% did not
achieve either response. As shown in Figure 1, overall
drug cost (cost 1) was €1,214,283 (€916,477 for treating
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HCV mono-infected patients; €297,805 for HIV/HCV
co-infected ones), and cost per SVR achieved was €22,284
(Figure 2).
Patients who achieved a RVR would not need a DAA,
but would only be treated with further 44 weeks of
PEG-IFN/RBV combination. The remaining 95 patients
would be eligible for DAA treatment. Among these
patients, according to the results of the ADVANCE trial,
55 would receive only 12 weeks of PEG-IFN/RBV after-
wards. The last 40 patients would need further 12 weeks
of PEG-IFN/RBV and DAA followed by 36 weeks of PEG-
IFN/RBV (according to 42% rate of detectable but ≤1,000
IU/ml HCV-RNA at weeks 4 or 12 of triple therapy) [9].
Using these estimates of virological response and length of
treatment, overall cost 2 was estimated to be €3,474,977
(see Figure 1). Corresponding cost per SVR achieved
resulted to be €44,643 (Figure 2).
Estimation of cost 3 was obtained by adding to cost 1
the cost for re-treatment with a DAA of the 47 patients
who did not achieve a SVR with PEG-IFN/RBV. Total
cost 3 would be € 3,002,094 (Figure 1). Cost for retreat-
ment of patients would be €1,179,195 for HCV mono-
infected patients and 608,617 for HIV/HCV co-infected
patients. Thus, total incremental cost (cost 3 minus cost
1) would be €1,787,812. The average cost per SVR
achieved would be €38,322 (Figure 2).
Table 1 Patient characteristics and treatment response (actual response to Peg-interferon + ribavirin or expected






n = 77 (74%) n = 27 (26%) n = 104 (100%)
Qualitative variables Gender:
Males (%) 37 (48) 6 (22) 43 (41)
Females (%) 40 (52) 21 (78) 61 (59)
Genotype:
1b (%) 60 (78) 16 (59) 76 (73)
1a (%) 11 (14) 10 (37) 21 (20)
1 (%) 6 (8) 1 (4) 7 (7)
RVR with PEG-IFN/RBV:
nonSVR RVR (%) 2 (3) 0 (0) 2 (2)
SVR RVR (%) 5 (6) 2 (8) 7 (7)
SVR nonRVR (%) 41 (53) 9 (33) 50 (48)
nonSVR nonRVR (%) 39 (38) 16 (59) 45 (43)
Response to PEG-INF/RBV (actual):
SVR (%) 46 (60) 11 (41) 57 (55)
Relapsers (%) 12 (15) 4 (15) 16 (15)
Partials (%) 2 (3) 4 (15) 6 (6)
Nulls (%) 17 (22) 8 (29) 25 (24)
Response to PEG-INF/RBV + DAA in
naïves (estimated):
SVR (%) 58 (75) 20 (75) 78 (75)
Non response (%) 19 (25) 7 (25) 26 (25)
Response to PEG-IFN/RBV in naïves plus
PEG-IFN/RBV + DAA in non responders
(estimated):
SVR (%) 62 (81) 19 (70) 81 (78)
Non response (%) 15 (19) 8 (30) 23 (22)
Quantitative variables Age (at PEG-IFN/RBV start):
Median 50 45 47
Range 20-70 36-60 20-70
IQR 23 7 17
Standard Deviation 14 5 12
Duration of PEG-IFN/RBV treatment in
weeks (actual):
Mean 44 40 42
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Discussion
This study estimated costs needed for treating with a
DAA containing regimen patients either experienced or
naive for PEG-IFN/RBV. Moreover, we projected future
costs against actual costs already incurred for treating
the naïve patients with only PEG-IFN/RBV. Lastly, we
compared costs for each SVR achieved. Our results will
provide local health authorities with an estimate of
resources needed to treat our patients with the currently
available DAAs. Clearly, the study was not aimed at
assessing cost-effectiveness. Further investigations using
either Markov model or cost-effectiveness analysis cal-
culations are therefore needed.
Patients who underwent treatment with PEG-IFN/RBV
reached a SVR in 55% cases overall, with a difference
between HCV mono-infected patients (60%) and HIV/
HCV co-infected ones (41%). In HCV mono-infected
patients, the rate of SVR in our study was even better that
Figure 1 Treatment costs (actual and estimated). NOTE: Cost 1 represents the actual cost incurred for treating the 104 patients under study
with Peg-interferon and ribavirin while naïve. Cost 2 represents the estimated cost of a lead-in strategy with PEG-IFN/RBV for 4 weeks, followed
by a directly acting antiviral for 12 or 36 weeks in the same patients while naïve. Cost 3 represents the estimated cost of PEG-IFN/RBV in naïve
patients (Cost 1) plus PEG-IFN/RBV with addition of a DAA in our patients who did not achieve a SVR.
Figure 2 Treatment cost per SVR (total costs were divided by the corresponding absolute numbers of SVR achieved or expected).
NOTE: Cost 1 represents the actual cost incurred for treating the 104 patients under study with Peg-interferon and ribavirin while naïve. Cost 2
represents the estimated cost of a lead-in strategy with PEG-IFN/RBV for 4 weeks, followed by a directly acting antiviral for 12 or 36 weeks in the
same patients while naïve. Cost 3 represents the estimated cost of PEG-IFN/RBV in naïve patients (Cost 1) plus PEG-IFN/RBV with addition of a
DAA in our patients who did not achieve a SVR.
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in two US registration trials, showing SVR rates of 54-56%
[12,13]. However, according to registration trials, the rate
of SVR after triple therapy is around 80% [9,10]. There-
fore, our results support the benefit of triple therapy over
dual therapy, which should be abandoned for treatment of
patients infected by genotype-1 HCV. Indeed, first genera-
tion DAAs showed to be cost-effective either in naïves or
IFN- experienced patients [11,14,15]. Moreover, second
generation DAAs, such as Sofosbuvir, were proved to be
cost effective in naive patients [16].
PEG-IFN/RBV has represented a scarcely effective ther-
apy in HIV/HCV co-infected patients with genotype 1, as
recorded in our study (41% SVR among HIV/HCV co-
infected patients). These low SVR rates impacted on total
drug expense. Indeed, although HIV+ patients represented
only 26% of our population they would weigh for 34% of
the entire sum needed for retreating experienced patients.
Because progression towards end stage liver disease
(cirrhosis, hepatocellular carcinoma and death) in HIV/
HCV co-infection is faster than HCV mono-infection,
co-infected patients with significant liver fibrosis are
urged to be treated for HCV as soon as possible [17].
During the 21st Conference on Retroviruses and Oppor-
tunistic Infection (CROI), two trials of the French
National Agency for Research on AIDS (ANRS) showed
high effectiveness of either TPR or BOC based regimens
among experienced HIV/HCV co-infected patients
(79.7% SVR after 24 weeks from end of therapy with
TPR, 53% SVR after 12 weeks from end of therapy with
BOC). Rates of discontinuation due to adverse events
(mostly haematological) were comprised between 10 and
20% [18,19]. Also, two real-life studies showed overall
SVR rates of 64% after 12 weeks from the end of ther-
apy with BOC or TPR [20,21]. At the same time, an
interferon free trial highlighted response rates close to
100% at week 12 of therapy with sofosbuvir plus ledipas-
vir [22]. However, in settings where safer and more
effective second generation DAAs are far from being
available, TPR and BOC could offer reasonable chances
to reach SVR, even if they are frequently affected by
severe drug toxicity.
Although the benefits of a DAA containing therapy
are well demonstrated (both for an increase in SVR and
for cost-effectiveness in terms of years of life gained
adjusting for quality of life), we found the cost for triple
therapy including DAA would be much greater (a three-
fold increase) than for PEG-IFN/RBV. Furthermore, the
cost for treating our patients who did not obtain a SVR
after PEG-IFN/RBV with DAA will be slightly greater
than the amount spent to treat these patients for the
first time (€1,787,812 versus €1,214,283). Lastly, mean
cost per SVR was two times greater for DAA than for
PEG-IFN/RBV treatment. Therefore, our findings
demonstrate that DAA will substantially impact the
economical budget of the national health system; infor-
mation which will be useful for planning future resource
allocation. Estimations are expected to increase further if
costs for monitoring and treatment of adverse effects
would be considered. Although it is possible that these
costs will decrease with newer regimens sparing PEG-
IFN, the above considerations suggest the opportunity to
decrease costs for therapies to improve sustainability.
Cammà et al. [11] found that the application of a lead-in
period with PEG-IFN/RBV would improve cost-effective-
ness because DAA are prescribed only to patients who
did not achieve a RVR measured at week 4. Furthermore,
Marcellin et al. [23] demonstrated that patients with
detectable HCV-RNA levels at week 4 but with a reduc-
tion of HCV-RNA by 3 log10 from baseline reached SVR
in a high percentage of cases (61%). In the present study,
we found that RVR rate in patients treated with PEG-
IFN/RBV was low (9%), but several patients achieved
SVR anyway (48%). This may be a reason why the esti-
mated cost for DAA in patients who completed PEG-
IFN/RBV without a SVR appeared to be smaller than the
cost estimated for treating only patients who did not
achieve a RVR with triple therapy, an approach that emu-
lates the lead-in strategy. Therefore, we can argue that a
prolongation of initial PEG-IFN/RBV could further
improve cost-effectiveness in the context of a lead-in
strategy. This may require further investigation.
Different subtypes of genotype 1 exhibit variable
response to double and triple therapy. It has been proven
that genotype 1a has a higher genetic barrier against
emergence of HCV resistance to TPR and BOC than gen-
otype 1b. Indeed, resistance to TPR and BOC in genotype
1a is caused by one single nucleotide substitution while at
least two different nucleotide substitutions are needed in
genotype 1b [24]. Also, a selection of a DAA molecule
more specific or appropriate for the control of a particu-
lar genotype, will certainly contribute to improve cost-
effectiveness and reduce the resources needed to treat
our patients.
This study is affected by some limitations. First, TPR
but not BOC was used for our estimations. Boceprevir is
a bit less expensive than TPR but length of treatment is
longer and number of pills is higher. For this reason,
there is a tendency to prefer TPR as first choice. Further
studies using BOC are required, however. Second, IL28B
polymorphism was not assessed in our patients. IL28B
has been shown to predict treatment response, so its con-
sideration in conjunction with RVR would further
improve cost-effectiveness [15]. Third, the cost impact of
genotype 1 subtypes, as well as of other genotypes of
HCV, was not evaluated in the present study, although it
will be addressed in a further manuscript in preparation.
Fourth, in our study, neither histological nor clinical condi-
tions (such as co-morbidities and liver disease assessment)
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could be considered, so, it was not possible to infer appro-
priately about clinical challenges in treating our population
with anti HCV drugs.
In conclusion, although cost effectiveness of TPR or
BOC in combination with PEG-IFN/RBV has been estab-
lished (when considering quality of life and prevention of
long-term complications of HCV), from the perspective
of the health care system, the cost for providing drugs
may limit prescriptions; especially in the current eco-
nomic crisis. So, we suggest that anti-HCV pipeline be
urgently implemented towards the production of even
more effective and cheaper drugs. While awaiting less
expensive drugs, proper pharmaco-economical studies
should be conducted to find more cost-effective schemes
and indications for treatment in clinical practice.
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